Ramachandran S Vasan1,2,3, Rebecca J Song3, Vanessa Xanthakis1,2,4, Alexa Beiser1,5,4, Charles DeCarli6, Gary F Mitchell7, Sudha Seshadri8. 1. Boston University's and National Heart, Lung, and Blood Institute's Framingham Heart Study, Framingham, MA (R.S.V., V.X., A.B.). 2. Section of Preventive Medicine and Epidemiology, Department of Medicine (R.S.V., V.X.), Boston University School of Medicine, MA. 3. Department of Epidemiology (R.S.V., R.J.S.), Boston University School of Public Health, Boston, MA. 4. Department of Biostatistics (V.X., A.B.), Boston University School of Public Health, Boston, MA. 5. Department of Neurology (A.B.), Boston University School of Medicine, MA. 6. University of California at Davis (C.D.). 7. Cardiovascular Engineering, Inc, Norwood, MA (G.F.M.). 8. Biggs Institute for Alzheimer's Disease, University of Texas Health Sciences Center at San Antonio (S.S.).
Abstract
BACKGROUND: Guidelines emphasize screening people with elevated BP for the presence of end-organ damage. METHODS: We characterized the prevalence, correlates, and prognosis of hypertension-mediated organ damage (HMOD) in the community-based Framingham Study. 7898 participants (mean age 51.6 years, 54% women) underwent assessment for the following HMOD: electrocardiographic and echocardiographic left ventricular hypertrophy, abnormal brain imaging findings consistent with vascular injury, increased carotid intima-media thickness, elevated carotid-femoral pulse wave velocity, reduced kidney function, microalbuminuria, and low ankle-brachial index. We characterized HMOD prevalence according to blood pressure (BP) categories defined by four international BP guidelines. Participants were followed up for incidence of cardiovascular disease. RESULTS: The prevalence of HMOD varied positively with systolic BP and pulse pressure but negatively with diastolic BP; it increased with age, was similar in both sexes, and varied across BP guidelines based on their thresholds defining hypertension. Among participants with hypertension, elevated carotid-femoral pulse wave velocity was the most prevalent HMOD (40%-60%), whereas low ankle-brachial index was the least prevalent (<5%). Left ventricular hypertrophy, reduced kidney function, microalbuminuria, increased carotid intima-media thickness, and abnormal brain imaging findings had an intermediate prevalence (20%-40%). HMOD frequently clustered within individuals. On follow-up (median, 14.1 years), there were 384 cardiovascular disease events among 5865 participants with concurrent assessment of left ventricular mass, carotid-femoral pulse wave velocity, kidney function, and microalbuminuria. For every BP category above optimal (referent group), the presence of HMOD increased cardiovascular disease risk compared with its absence. CONCLUSIONS: The prevalence of HMOD varies across international BP guidelines based on their different thresholds for defining hypertension. The presence of HMOD confers incremental prognostic information regarding cardiovascular disease risk at every BP category.
BACKGROUND: Guidelines emphasize screening people with elevated BP for the presence of end-organ damage. METHODS: We characterized the prevalence, correlates, and prognosis of hypertension-mediated organ damage (HMOD) in the community-based Framingham Study. 7898 participants (mean age 51.6 years, 54% women) underwent assessment for the following HMOD: electrocardiographic and echocardiographic left ventricular hypertrophy, abnormal brain imaging findings consistent with vascular injury, increased carotid intima-media thickness, elevated carotid-femoral pulse wave velocity, reduced kidney function, microalbuminuria, and low ankle-brachial index. We characterized HMOD prevalence according to blood pressure (BP) categories defined by four international BP guidelines. Participants were followed up for incidence of cardiovascular disease. RESULTS: The prevalence of HMOD varied positively with systolic BP and pulse pressure but negatively with diastolic BP; it increased with age, was similar in both sexes, and varied across BP guidelines based on their thresholds defining hypertension. Among participants with hypertension, elevated carotid-femoral pulse wave velocity was the most prevalent HMOD (40%-60%), whereas low ankle-brachial index was the least prevalent (<5%). Left ventricular hypertrophy, reduced kidney function, microalbuminuria, increased carotid intima-media thickness, and abnormal brain imaging findings had an intermediate prevalence (20%-40%). HMOD frequently clustered within individuals. On follow-up (median, 14.1 years), there were 384 cardiovascular disease events among 5865 participants with concurrent assessment of left ventricular mass, carotid-femoral pulse wave velocity, kidney function, and microalbuminuria. For every BP category above optimal (referent group), the presence of HMOD increased cardiovascular disease risk compared with its absence. CONCLUSIONS: The prevalence of HMOD varies across international BP guidelines based on their different thresholds for defining hypertension. The presence of HMOD confers incremental prognostic information regarding cardiovascular disease risk at every BP category.
Authors: Harm H H Feringa; Jeroen J J Bax; Virginie H van Waning; Eric Boersma; Abdou Elhendy; Olaf Schouten; Marco J Tangelder; Marc H R M van Sambeek; Anton H van den Meiracker; Don Poldermans Journal: Arch Intern Med Date: 2006-03-13
Authors: Bryan Williams; Giuseppe Mancia; Wilko Spiering; Enrico Agabiti Rosei; Michel Azizi; Michel Burnier; Denis L Clement; Antonio Coca; Giovanni de Simone; Anna Dominiczak; Thomas Kahan; Felix Mahfoud; Josep Redon; Luis Ruilope; Alberto Zanchetti; Mary Kerins; Sverre E Kjeldsen; Reinhold Kreutz; Stephane Laurent; Gregory Y H Lip; Richard McManus; Krzysztof Narkiewicz; Frank Ruschitzka; Roland E Schmieder; Evgeny Shlyakhto; Costas Tsioufis; Victor Aboyans; Ileana Desormais Journal: Eur Heart J Date: 2018-09-01 Impact factor: 29.983
Authors: Greta Lee Splansky; Diane Corey; Qiong Yang; Larry D Atwood; L Adrienne Cupples; Emelia J Benjamin; Ralph B D'Agostino; Caroline S Fox; Martin G Larson; Joanne M Murabito; Christopher J O'Donnell; Ramachandran S Vasan; Philip A Wolf; Daniel Levy Journal: Am J Epidemiol Date: 2007-03-19 Impact factor: 4.897
Authors: Aleksandra Pikula; Alexa S Beiser; Charles DeCarli; Jayandra J Himali; Stephanie Debette; Rhoda Au; Jacob Selhub; Geoffrey H Toffler; Thomas J Wang; James B Meigs; Margaret Kelly-Hayes; Carlos S Kase; Philip A Wolf; Ramachandran S Vasan; Sudha Seshadri Journal: Circulation Date: 2012-03-28 Impact factor: 29.690
Authors: S F Quan; B V Howard; C Iber; J P Kiley; F J Nieto; G T O'Connor; D M Rapoport; S Redline; J Robbins; J M Samet; P W Wahl Journal: Sleep Date: 1997-12 Impact factor: 5.849
Authors: Andreas Fuchs; J Tobias Kühl; Per E Sigvardsen; Andreas D Knudsen; Emma Julia P Nilsson; Zara R Stisen; Jørgen L Jeppesen; Børge G Nordestgaard; Lars V Køber; Klaus F Kofoed Journal: J Hypertens Date: 2021-04-01 Impact factor: 4.844
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391
Authors: Thomas Sehestedt; Jørgen Jeppesen; Tine W Hansen; Kristian Wachtell; Hans Ibsen; Christian Torp-Pedersen; Christian Torp-Petersen; Per Hildebrandt; Michael H Olsen Journal: Eur Heart J Date: 2009-12-23 Impact factor: 29.983